Vyant Bio, Inc.
VYNTDelisted May 4, 2023- Industry
- Services-Medical Laboratories
- SEC CIK
- 0001349929
Vyant Bio, Inc. was delisted on May 4, 2023; its insiders filed their last Form 4 on Feb 27, 2023; 17 institutions reported holding it in 13F filings for Q1 2023, worth $136.8K in total; no superinvestor held it.
13F holders, Q4 2022
Institutional positions in Vyant Bio, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 17
- −9 vs. Q3 2022
- Shares held
- 318.2K
- −1.38M (−81.3%) vs. Q3 2022
- Total value
- $222.1K
- −$727.2K (−76.6%) vs. Q3 2022
- New holders
- 3
- 0 more added
- Sold out
- 12
- 14 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VYNT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 1 | $1 |
| Q1 2023 | 17 | $136.8K |
| Q4 2022 | 17 | $222.1K |
| Q3 2022 | 26 | $949.3K |
| Q2 2022 | 21 | $1.47M |
| Q1 2022 | 23 | $2.54M |
| Q4 2021 | 27 | $3.12M |
| Q3 2021 | 23 | $5.27M |
| Q2 2021 | 29 | $8.41M |
| Q1 2021 | 18 | $2.96M |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Vyant Bio, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Advisor Group Holdings, Inc. | 24 | $0 | 0.00% | −96−80.0% | Reduced |
| Royal Bank of Canada | 3 | $0 | 0.00% | +3 | New |
| Barclays PLC | 3 | $2 | 0.00% | −12−80.0% | Reduced |
| FMR LLC | 3 | $2 | 0.00% | −23−88.5% | Reduced |
| Wells Fargo & Company | 30 | $21 | 0.00% | −116−79.5% | Reduced |
| Morgan Stanley | 333 | $234 | 0.00% | −19,719−98.3% | Reduced |
| UBS Group AG | 4,955 | $3.47K | 0.00% | −9,029−64.6% | Reduced |
| US Bancorp | 4,962 | $3.49K | 0.00% | −19,851−80.0% | Reduced |
| Citadel Advisors LLC | 11,224 | $7.88K | 0.00% | −10,334−47.9% | Reduced |
| Virtu Financial LLC | 11,568 | $8.00K | 0.00% | −4,250−26.9% | Reduced |
| Renaissance Technologies LLC | 14,320 | $10.0K | 0.00% | −6,480−31.2% | Reduced |
| State Street Corp | 15,038 | $10.6K | 0.00% | −60,162−80.0% | Reduced |
| HRT Financial LP | 16,911 | $11.0K | 0.00% | +16,911 | New |
| BlackRock Inc. | 26,558 | $18.7K | 0.00% | −106,239−80.0% | Reduced |
| Mayo Clinic | 27,742 | $19.4K | 0.01% | +27,742 | New |
| Geode Capital Management, LLC | 38,820 | $27.0K | 0.00% | −155,766−80.0% | Reduced |
| Vanguard Group Inc | 145,719 | $102.4K | 0.00% | −611,080−80.7% | Reduced |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −202,725−100.0% | Sold out |
| Northern Trust Corp | 0 | $0 | 0.00% | −43,901−100.0% | Sold out |
| Jackson Square Capital, LLC | 0 | $0 | 0.00% | −30,389−100.0% | Sold out |
| Cambridge Investment Research Advisors, Inc. | 0 | $0 | 0.00% | −21,460−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −21,537−100.0% | Sold out |
| Country Club Bank | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| NorthRock Partners, LLC | 0 | $0 | 0.00% | −18,832−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −16,605−100.0% | Sold out |
| AE Wealth Management LLC | 0 | $0 | 0.00% | −13,933−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −12,646−100.0% | Sold out |
| Carlson Capital Management | 0 | $0 | 0.00% | −11,800−100.0% | Sold out |
| Mariner, LLC | 0 | $0 | 0.00% | −10,273−100.0% | Sold out |